1Hensley ML, Schuchter LM, Lindley C et al. American society of clinical oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol,1999,17(10):3333.
2Koukourakle MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs,2002,13(3):181.
3Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol,1999,26(2Suppl 7):3.
4Snyder RD, Grdina DJ. Further evidence that the radioprotective aminothiol, WR-1065, catalytically inactivates mammalian topoisomerase Ⅱ. Cancer Res,2000, 60(5):1186.
5Trog D, Bank P, Wendt TG et al. Daily amifostine given concomitantly to chemoradiation in head and neck cancer: A pilot study. Strahlenther onkol, 1999, 175(9):444.
6Wasserman T, Mackowiak JI, Brizel DM et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Onkol Biol Phys, 2000, 48(4): 1035.
7Selvaggi G, Belani CP. Carboplatin and paclitaxel in non-small cell lung cancer:the role of amifostine. Semin Oncol,1999,26(2 Suppl 7):51.
8Gridelli C,Guida C, Barletta E et al. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. Lung Cancer, 2000,29(2):131.
9Alberts DS. Future directions in gynecologic cancer. Semin Oncol, 1999,26 (2Suppl 7): 125.
10Facorro G, Sarrasague MM, Torti H et al. Oxidative study of patients with total bodyirradiation: effects of amifostine treatment. Bone Marrow Transplant, 2004,33(8):793.
